-
Mashup Score: 4
The APC Executive Committee is highly conscientious of the impact that the current COVID-19 pandemic has on travel and event restrictions. We strongly believe in mitigating the spread of the virus while still maintaining the ability to facilitate the exchange between experts, and positively impact the lives of patients with advanced prostate cancer.Therefore the APCCC 2022 is planned as a hybrid…
Source: www.apccc.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 2
The APC Executive Committee is highly conscientious of the impact that the current COVID-19 pandemic has on travel and event restrictions. We strongly believe in mitigating the spread of the virus while still maintaining the ability to facilitate the exchange between experts, and positively impact the lives of patients with advanced prostate cancer.Therefore the APCCC 2022 is planned as a hybrid…
Source: www.apccc.orgCategories: Latest Headlines, UrologyTweet-
RT @APCCC_Lugano: The #APCCC22 draft programme is now available on our website! Check it out 👉 https://t.co/Kc7Cd9sAU3 #prostatecancer htt…
-
-
Mashup Score: 6ICECaP - Movember aligning to a shared goal - 3 year(s) ago
Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer.
Categories: Latest Headlines, Oncologists1Tweet-
Thanks @TallAllen - in collaboration with STAMPEDE and EnzaMet teams and @AttardLab we are aiming to confirm the reproducibility of benefit in luminal B (@anis_a_hamid 1st author Ann Onc 2021) paper. Details at https://t.co/8gQM6oiqn6 https://t.co/W8c7GQ5u1G
-
-
Mashup Score: 0ICECaP - Movember aligning to a shared goal - 3 year(s) ago
Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer.
Categories: Latest Headlines, UrologyTweet-
A big thanks to the whole https://t.co/8gQM6oiqn6 community for enabling the SPAIG award from American Statistical Association @Movember @DanaFarber_GU @Merregan @Wanling50578056 https://t.co/C9Ah2Ez7dU
-
-
Mashup Score: 3
The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTE…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Free access to Abitaterone +/- Ipatasertib phase 3 trial in first line castration resistant PrCa @ https://t.co/NQOdAk6Gs8 Benefits of targeting PI3kinase/AKT in PrCa are being realized. Kudos to basic and clinical scientists who committed many years to this biology @Uromigos
-
-
Mashup Score: 1ICECaP - Movember aligning to a shared goal - 3 year(s) ago
Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Indeed Professor D’Amico and @Wanling50578056 have already made preparations to incorporate the data with ICECaP repository https://t.co/8gQM6oiqn6 for Individual patient data secondary treatment effect meta analyses @Uromigos with the other docetaxel adjuvant studies https://t.co/ltpq4fcJC9
-
-
Mashup Score: 3ICECaP - Movember aligning to a shared goal - 3 year(s) ago
Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Congrats @neerajaiims for a co-op grp ph 3 mHSPC trial. Alternate hypothesis for long OS: pts referred to S1216 less likely to benefit from docet = metach met and/or low vol = better prognosis. Lets define better prog variables together! -> https://t.co/8gQM6oiqn6 @Uromigos https://t.co/BdY8tl5SEM
-
-
Mashup Score: 2
The APC Executive Committee is highly conscientious of the impact that the current COVID-19 pandemic has on travel and event restrictions. We strongly believe in mitigating the spread of the virus while still maintaining the ability to facilitate the exchange between experts, and positively impact the lives of patients with advanced prostate cancer.Therefore the APCCC 2022 is planned as a hybrid…
Source: www.apccc.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Polling: 74.3% of respondents consider Testo Supp + abi/apa/enza most appropriate control arm for oligomet HSPC trials. It will be interesting to hear discussion @APCCC_Lugano Oct 9, 2021 program @ https://t.co/8Pbi0ixo8O @Uromigos @DanaFarber_GU @Silke_Gillessen @PCF_Science https://t.co/mBd1NwSN6e https://t.co/IIZJNTfdT9
-
-
Mashup Score: 2Please wait whilst we redirect you - 3 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#ENZAMET shows 60% increase in OS / incr 3 yr OS from 83% to 92% at 33 months follow-up for pts with metach low vol mHSPC https://t.co/5YnBdl8jiu Should control arm for SBRT oligomet HSPC trials be? @ANZUPtrials @Uromigos @APCCC_Lugano @DanaFarber_GU @PCF_Science @EUplatinum
-
-
Mashup Score: 0Please wait whilst we redirect you - 3 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
... continued 4) is #3 / SBRT "reasonable" with incr 3y OS from 83% to 92% for metach low vol with enzalutimde in #ENZAMET and supported by apalutamide #TITAN @ANZUPtrials @APCCC_Lugano @Prof_IanD @Uromigos @scserendipity1 @DanaFarber_GU @neerajaiims https://t.co/5YnBdl8jiu https://t.co/iXsX36uqi7
-
RT @APCCC_Lugano: We have developed 135 #consensus questions for @APCCC_Lugano in April 2022 https://t.co/U46NMslfll with our friends: @Alb…